Captor Therapeutics S.A. Logo

Captor Therapeutics S.A.

Develops Targeted Protein Degradation therapies for cancer and autoimmune diseases.

CTX | WAR

Overview

Corporate Details

ISIN(s):
PLCPTRT00014 (+1 more)
LEI:
259400JHH1S2I2S4O735
Country:
Poland
Address:
Wrocław Duńska 11, 54-427 Wrocław

Description

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-03-21 14:55
Zmiana terminu publikacji raportów rocznych za 2021 rok. - Content (PL)
Polish 898 bytes
2022-03-11 18:07
Zawarcie opcyjnej umowy na licencję wyłączną z University of Michigan i Michiga…
Polish 2.2 KB
2022-03-09 09:32
Informacja nt. otrzymania korzystnego orzeczenia WSA w sprawie interpretacji po…
Polish 2.2 KB
2022-03-07 17:50
Rejestracja zmiany Statutu Spółki - Content (PL)
Polish 3.0 KB
2022-02-24 21:58
Asymilacja akcji zwykłych na okaziciela Emitenta - Content (PL)
Polish 598 bytes
2022-02-24 18:35
Informacja o postępie w badaniach badawczo-rozwojowych związanych z projektem C…
Polish 2.6 KB
2022-02-23 22:40
Uchwała Zarządu GPW w sprawie dopuszczenia i wprowadzenia do obrotu giełdowego …
Polish 945 bytes
2022-02-21 17:16
Wykaz akcjonariuszy posiadających na Nadzwyczajnym Walnym Zgromadzeniu Spółki z…
Polish 1.9 KB
2022-02-21 17:05
Załącznik do raportu
Polish 199.5 KB
2022-02-21 17:05
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie 21 luty 2022 r. - …
Polish 644 bytes
2022-02-10 17:34
Odstąpienie od podpisania umowy z Agencją Badań Medycznych - Content (PL)
Polish 1.5 KB
2022-02-07 15:07
Zawarcie umowy na zorganizowanie i kompleksowe przeprowadzenie badania kliniczn…
Polish 2.4 KB
2022-01-28 15:55
Życiorysy Członków Zarządu
Polish 563.7 KB
2022-01-28 15:55
Powołanie Członków Zarządu OncoArendi Therapeutics S.A. - Content (PL)
Polish 1.1 KB
2022-01-27 22:16
Terminy publikacji raportów okresowych w roku 2022 - Content (PL)
Polish 1.9 KB

Automate Your Workflow. Get a real-time feed of all Captor Therapeutics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Captor Therapeutics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Captor Therapeutics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.